Literature DB >> 24319201

Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.

Michael R Verneris1.   

Abstract

Two of the major complications that limit the efficacy of allogeneic hematopoietic cell transplantation (allo-HCT) are disease relapse and GVHD. Due to their rapid recovery early after allo-HCT and their ability to kill malignant targets without prior exposure, natural killer (NK) cells have been considered one of the main effector cells that mediate early GVL reactions. Conversely, regulatory T ells (Tregs) have proven to be critical in facilitating self-tolerance. Both murine and human studies have demonstrated a significant role for Tregs in the modulation of GVHD after allo-HCT. This article reviews the mechanisms of how these 2 cell types carry out these functions, focusing on the post-allo-HCT period. Surprisingly, relatively few studies have addressed how Tregs and NK cells interact with one another and whether these interactions are antagonistic. Although preclinical studies suggest active cross-talk between NK cells and Tregs, early clinical studies have not shown a detrimental impact of Treg therapy on relapse. Despite this, interruption of tolerogenic signals may enhance the efficacy of NK effector functions. Methods to transiently impair Treg functions and augment NK cell alloreactivity will be discussed.

Entities:  

Mesh:

Year:  2013        PMID: 24319201      PMCID: PMC4020013          DOI: 10.1182/asheducation-2013.1.335

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  60 in total

1.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

2.  Licensing of natural killer cells by host major histocompatibility complex class I molecules.

Authors:  Sungjin Kim; Jennifer Poursine-Laurent; Steven M Truscott; Lonnie Lybarger; Yun-Jeong Song; Liping Yang; Anthony R French; John B Sunwoo; Suzanne Lemieux; Ted H Hansen; Wayne M Yokoyama
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

Review 3.  NK cell receptors.

Authors:  L L Lanier
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Severe herpesvirus infections in an adolescent without natural killer cells.

Authors:  C A Biron; K S Byron; J L Sullivan
Journal:  N Engl J Med       Date:  1989-06-29       Impact factor: 91.245

5.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

Authors:  Margaret L Green; Wendy M Leisenring; Hu Xie; Roland B Walter; Marco Mielcarek; Brenda M Sandmaier; Stanley R Riddell; Michael Boeckh
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

6.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.

Authors:  Jeffrey S Miller; Yvette Soignier; Angela Panoskaltsis-Mortari; Sarah A McNearney; Gong H Yun; Susan K Fautsch; David McKenna; Chap Le; Todd E Defor; Linda J Burns; Paul J Orchard; Bruce R Blazar; John E Wagner; Arne Slungaard; Daniel J Weisdorf; Ian J Okazaki; Philip B McGlave
Journal:  Blood       Date:  2005-01-04       Impact factor: 22.113

7.  Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.

Authors:  Roberta Castriconi; Claudia Cantoni; Mariella Della Chiesa; Massimo Vitale; Emanuela Marcenaro; Romana Conte; Roberto Biassoni; Cristina Bottino; Lorenzo Moretta; Alessandro Moretta
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-19       Impact factor: 11.205

8.  Lymphocyte recovery after allogeneic bone marrow transplantation predicts risk of relapse in acute lymphoblastic leukemia.

Authors:  S Kumar; M G Chen; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; A Tefferi; M R Litzow
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

9.  Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors.

Authors:  S Yamasaki; H Henzan; Y Ohno; T Yamanaka; T Iino; Y Itou; M Kuroiwa; M Maeda; N Kawano; N Kinukawa; T Miyamoto; K Nagafuji; K Shimoda; S Inaba; S Hayashi; S Taniguchi; T Shibuya; H Gondo; T Otsuka; M Harada
Journal:  Bone Marrow Transplant       Date:  2003-09       Impact factor: 5.483

Review 10.  Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis.

Authors:  A Moretta; C Bottino; M Vitale; D Pende; C Cantoni; M C Mingari; R Biassoni; L Moretta
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

View more
  11 in total

1.  Association of peripheral NK cell counts with Helios+ IFN-γ- Tregs in patients with good long-term renal allograft function.

Authors:  K Trojan; L Zhu; M Aly; R Weimer; N Bulut; C Morath; G Opelz; V Daniel
Journal:  Clin Exp Immunol       Date:  2017-03-13       Impact factor: 4.330

2.  Immunological impact of Wharton's Jelly mesenchymal stromal cells and natural killer cell co-culture.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  Mol Cell Biochem       Date:  2018-01-30       Impact factor: 3.396

3.  Mesenchymal stromal cells of the bone marrow and natural killer cells: cell interactions and cross modulation.

Authors:  Mehdi Najar; Mohammad Fayyad-Kazan; Nathalie Meuleman; Dominique Bron; Hussein Fayyad-Kazan; Laurence Lagneaux
Journal:  J Cell Commun Signal       Date:  2018-01-19       Impact factor: 5.782

4.  Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study.

Authors:  Xiang-Yu Zhao; Xiao-Su Zhao; Yu-Tong Wang; Yu-Hong Chen; Lan-Ping Xu; Xiao-Hui Zhang; Wei Han; Huan Chen; Yu Wang; Chen-Hua Yan; Feng-Rong Wang; Jing-Zhi Wang; Kai-Yan Liu; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2016-10-28       Impact factor: 8.110

Review 5.  Immunological effects of hypomethylating agents.

Authors:  Katherine E Lindblad; Meghali Goswami; Christopher S Hourigan; Karolyn A Oetjen
Journal:  Expert Rev Hematol       Date:  2017-07-03       Impact factor: 2.929

Review 6.  Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.

Authors:  Zachary B Davis; Martin Felices; Michael R Verneris; Jeffrey S Miller
Journal:  Cancer J       Date:  2015 Nov-Dec       Impact factor: 3.360

7.  CCR7 expressing mesenchymal stem cells potently inhibit graft-versus-host disease by spoiling the fourth supplemental Billingham's tenet.

Authors:  Hong Li; Yan-Ming Jiang; Yan-Feng Sun; Ping Li; Rui-Jie Dang; Hong-Mei Ning; Yu-Hang Li; Ying-Jie Zhang; Xiao-Xia Jiang; Xi-Min Guo; Ning Wen; Yan Han; Ning Mao; Hu Chen; Yi Zhang
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

Review 8.  Human mesenchymal stem cells (MSCs) for treatment towards immune- and inflammation-mediated diseases: review of current clinical trials.

Authors:  Li-Tzu Wang; Chiao-Hsuan Ting; Men-Luh Yen; Ko-Jiunn Liu; Huey-Kang Sytwu; Kenneth K Wu; B Linju Yen
Journal:  J Biomed Sci       Date:  2016-11-04       Impact factor: 8.410

9.  The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch.

Authors:  Alexander A Celik; Thomas Kraemer; Trevor Huyton; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2015-11-09       Impact factor: 2.846

Review 10.  Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.

Authors:  Lingling Zhang; Jianhua Yu; Wei Wei
Journal:  Front Immunol       Date:  2018-05-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.